ARS Pharmaceuticals, Inc. $SPRY Shares Sold by General American Investors Co. Inc.

General American Investors Co. Inc. decreased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 19.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 908,428 shares of the company’s stock after selling 224,618 shares during the period. General American Investors Co. Inc.’s holdings in ARS Pharmaceuticals were worth $3,915,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. USAdvisors Wealth Management LLC bought a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $43,000. Inscription Capital LLC bought a new position in ARS Pharmaceuticals during the third quarter worth about $56,000. Bessemer Group Inc. raised its stake in ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after purchasing an additional 7,290 shares in the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in ARS Pharmaceuticals in the 1st quarter worth about $80,000. Finally, Syon Capital LLC bought a new stake in ARS Pharmaceuticals in the 2nd quarter valued at about $80,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Key ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: ARS said neffy’s U.S. market share has surpassed 5% and is targeting cash-flow breakeven by year-end 2027, offering investors signs of product adoption and a longer-term financial milestone. Article: ARS targets cash-flow breakeven as neffy share surpasses 5%
• Neutral Sentiment: Raymond James cut its rating from Strong Buy to Outperform but maintained a $17 price target. The downgrade may temper sentiment, though the firm’s revised rating remains positive. Article: Raymond James rating and price target
• Negative Sentiment: Third-quarter results fell short of expectations: ARS reported a $0.36-per-share loss versus an approximately $0.30 consensus loss, while revenue of $37.71 million missed the $41.99 million estimate. The shortfall could weigh on near-term sentiment. Article: ARS reports Q3 loss and misses revenue estimates

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th. Weiss Ratings downgraded shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Finally, Raymond James Financial downgraded shares of ARS Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.33.

ARS Pharmaceuticals Price Performance

SPRY traded up $0.14 on Friday, hitting $2.79. 5,672,082 shares of the stock were exchanged, compared to its average volume of 1,668,914. ARS Pharmaceuticals, Inc. has a 12 month low of $2.44 and a 12 month high of $13.15. The business has a 50-day moving average of $4.29 and a two-hundred day moving average of $7.22. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The firm has a market capitalization of $277.47 million, a price-to-earnings ratio of -1.38 and a beta of 0.98.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. The firm had revenue of $37.71 million for the quarter, compared to analyst estimates of $41.99 million. Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -1.91 EPS for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.